
In a phase II study of metastatic colorectal cancer (mCRC) patients treated with trifluridine/tipiracil (FTD/TPI), circulating tumor DNA (ctDNA) levels were linked to survival outcomes. High ctDNA levels (≥5%) and increasing tumor levels over time were associated with poorer survival. These findings suggest that ctDNA can help identify patients who are unlikely to benefit from FTD/TPI, potentially reducing unnecessary treatments and improving quality of life.
Like
Save
Share